dicyandiamido (cyanoguanidine)

04/01/2011 - "In conclusion, in this present study we have demonstrated that BPR-DC-2, derived from a series of novel synthetic cyclic cyanoguanidine compounds, has proved its potential as an anti-tumor drug candidate in treating lung cancer."
08/01/2002 - "CHS 828, a pyridyl cyanoguanidine, is a new drug candidate now in phase I/II trials, that has shown promising anticancer activity in experimental tumor models and primary cultures of cancer cells from patients. "
11/01/2001 - "CHS 828 is a pyridyl cyanoguanidine that has shown promising preclinical anticancer activity against various experimental tumor models and is presently being tested in a phase II trial in man. "
01/01/2004 - "Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828."
09/01/2002 - "CHS 828 is a cyanoguanidine, which has demonstrated potent antitumor activity in preclinical tumor models. "

11/29/2007 - "Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder."
01/19/2004 - "Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder."

04/01/2011 - "Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer."
04/01/2011 - "In this present study, it is our aim to screen more potential candidates among the cyclic pyridyl cyanoguanidine compounds (BPR-DC-1, 2, 3) by in vitro and in vivo studies for the therapy of lung cancer, alternatively. "
04/01/2011 - "In conclusion, in this present study we have demonstrated that BPR-DC-2, derived from a series of novel synthetic cyclic cyanoguanidine compounds, has proved its potential as an anti-tumor drug candidate in treating lung cancer."

01/01/2001 - "Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells."
04/15/2002 - "The role of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) and the ADP-ribosylation inhibitor 3-aminobenzamide (3-ABA) in the cytotoxicity induced by the novel antitumoral cyanoguanidine CHS 828 was investigated in the human lymphoma cell line U-937 GTB. "

03/26/1965 - "Dicyandiamide promotes certain dehydration condensations under conditions possible on primitive Earth. "
12/01/2006 - "It was found that the carbodiimides cyanamide and dicyandiamide dramatically lowered the temperature at which thermal dehydration of the acid led to anhydride formation. "